PubMed Health⌕ Search

PubMed · 8047772

[Genetics of glaucoma].

Abstract

The glaucomas are the second cause of blindness in the industrialized world. As well as all other pathologies, they take advantage of recent developments in the field of the molecular biology. The run for the pathological genes has just begun. Indeed, in Mai 1993, the first pathological gene was localized on the long arm of chromosome 1q21-q31 in every involved members of a family with juvenile glaucoma. Sequencing of the gene is in progress and should be soon successful. The multitude of clinical glaucoma forms lets foresee several pathological genes. Nosological associations known since long time as glaucoma and diabetes mellitus (certain forms) seem assumed to common chromosomic anomalies. The different types of glaucomas and the most frequent ocular anomalies with glaucoma were examined under the genetic point of view. Whereas the juvenile glaucomas are transmitted according a autosomal dominant pattern with a almost full penetrance, the primary open angle glaucomas are transmitted according a multifactorial mode. This fundamental difference between the diverse forms of glaucomas could have large outcomes on the evolution of the knowledges of the disease and its treatment. The discovery of the genetical anomalies responsible for glaucomas should, in the next three decades, transform radically the treatment of glaucoma. Of symptomatic by lowering of the intraocular pressure, the treatment will become ethiological, either pharmacological through correction of production of the pathological gene, either genic through direct correction of the gene.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

X D Martin. 1994. [Genetics of glaucoma].. https://pubmed.ncbi.nlm.nih.gov/8047772/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Small Copy Number Neutral Intrachromosomal Translocation of PAX6 and Aniridia.

IMPORTANCE: Approximately 5% to 10% of individuals with classic aniridia do not receive a molecular diagnosis after clinical testing for variants in PAX6 and its downstream regulatory region. OBJECTIVE: To apply optical genome mapping (OGM) and long-read whole-genome sequencing (lrWGS) to diagnose an individual with unexplained classic aniridia. DESIGN, SETTING, AND PARTICIPANTS: High-quality DNA was extracted from the blood of a 16-year-old male patient with classic aniridia and prior negative clinical test results that included sequencing and copy number analysis of PAX6 exons and downstream regulatory region as well as genomic analysis via short-read whole-genome sequencing (srWGS) and analyzed using OGM and lrWGS. All analyses were performed in a research laboratory in Wisconsin from January 2019 to September 2025. INTERVENTIONS: OGM and lrWGS. MAIN OUTCOMES AND MEASURES: Identification of a structural variant disrupting PAX6 expression in an individual with classic aniridia, following negative prior testing including srWGS. RESULTS: OGM identified a 55-kb deletion on 11p13 encompassing all PAX6 exons and exon 12 of ELP4, with insertion of this segment into 11q21. lrWGS delineated the exact breakpoints, confirming that the downstream regulatory region, required for normal PAX6 expression, remained at the 11p13 locus. Consequently, the translocated copy of PAX6 at 11q21 is expected to lack expression due to the loss of its essential regulatory elements. CONCLUSIONS AND RELEVANCE: These findings in an individual with classic aniridia harboring an intrachromosomal rearrangement at the PAX6 locus identified by OGM and lrWGS may represent the smallest reported structural variant to separate the PAX6 coding sequence from its downstream regulatory region. This structural variant may have fallen below the detection threshold of srWGS due to its balanced nature and small size, suggesting OGM and lrWGS would be needed for definitive identification.

Aniridia↗

Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.

Despite aggressive salvage regimens, approximately half of all children who suffer a Wilms' tumour recurrence will die of their disease. Although there are increasing data on molecular genetic prognostic factors present in the tumour at diagnosis, there is little information regarding the molecular events that occur with Wilms' tumour progression and relapse. In the present study, microarray-based comparative genomic hybridization (aCGH) analysis has been carried out on 58 Wilms' tumour samples, which included 38 untreated primary and 20 recurrent tumours. A higher degree of copy number changes was observed in the recurrent tumours (33.0% genomic clones) than in the primary tumour (21.2%). Paired analysis highlighted the acquisition of 15q gain with high levels of IGF1R expression in the tumour recurrence in two cases. The most statistically significant abnormality acquired between diagnosis and relapse was loss of 17p. One case that experienced 17p loss was classified as favourable histology at diagnosis, but exhibited diffuse anaplasia at recurrence and had a homozygous TP53 deletion. Another instructive case with a constitutional 11p13 deletion presented with bilateral tumours and suffered two subsequent recurrences in the left kidney. A somatic WT1 mutation was found only in the right kidney tumour, while the constitutional 11p13 deletion was the only abnormality detected in the initial left kidney tumour by aCGH. The two subsequent relapses in the left kidney contained an accumulation of additional genetic alterations, including an independent WT1 mutation.

Aniridia↗